THERAPIX BIOSCIENCES LTD Inactive Instrument
Therapix Biosciences Ltd Stock TEL AVIV STOCK EXCHANGE
Equities
IL0010951403
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
||
| - ILa | - |
|
| Apr. 11 | SciSparc Ltd. signed a merger agreement to acquire remaining stake in Automax Motors Ltd. | CI |
| Apr. 01 | SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.35 500.56 | Sales 2023 | 2.88 1.07K | Capitalization | 2.56M 950M |
|---|---|---|---|---|---|
| Net income 2022 | -2M -743M | Net income 2023 | -5M -1.86B | EV / Sales 2022 | 1,145,812 x |
| Net cash position 2022 | 3.55M 1.32B | Net cash position 2023 | 5M 1.86B | EV / Sales 2023 | -848,893 x |
| P/E ratio 2022 |
-1.33
x | P/E ratio 2023 |
-0.34
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
More press releases
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +21.59% | 44.15B | |
| +23.03% | 23.02B | |
| +18.55% | 15.33B | |
| +12.26% | 13.74B | |
| +52.55% | 12.16B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.88% | 5.66B |
